Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.
In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.
Biostatistics Center, and.|Medical Practice Evaluation Center, Massachusetts General Hospital.|Harvard Medical School.|Harvard University Center for AIDS Research.
Robert A
RA
Parker
Biostatistics Center, and.
Dustin J
DJ
Rabideau
Harvard Medical School.|Division of Infectious Diseases, Brigham and Women's Hospital, and.
Paul E
PE
Sax
Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Camlin
C
Tierney
Division of HIV Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, and.|David Geffen School of Medicine at UCLA, Los Angeles, California.
Eric S
ES
Daar
Division of Allergy and Infectious Diseases, University of Washington, Seattle; and.
Ann C
AC
Collier
Medical Practice Evaluation Center, Massachusetts General Hospital.|Harvard Medical School.|Harvard University Center for AIDS Research.|Department of Orthopedic Surgery, Brigham and Women's Hospital.|Department of Epidemiology, Boston University School of Public Health.|Department of Biostatistics, Boston University School of Public Health.
Elena
E
Losina
Medical Practice Evaluation Center, Massachusetts General Hospital.|Harvard Medical School.|Harvard University Center for AIDS Research.|Department of Epidemiology, Boston University School of Public Health.|Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, and.|Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts.
Kenneth A
KA
Freedberg
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D055118:Medication Adherence; D012367:RNA, Viral / Q000097:blood; D057566:Self Report; D000068698:Tenofovir / Q000008:administration & dosage / Q000627:therapeutic use; D017211:Treatment Failure; D019562:Viral Load / Q000187:drug effects; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D012367:RNA, Viral; D000068698:Tenofovir; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir
HIV; adherence; missing medication; self-report; virologic failure.